Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Sclerosis, Relapsing-Remitting 1Hypocalcemia 1Hyperparathyroidism, Secondary 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Cyclophosphamide 409Methotrexate 246Cytarabine 231Vincristine 188fludarabine phosphate 172Dexamethasone 169fludarabine 143Etoposide 143Peripheral Blood Stem Cell Transplantation 136Filgrastim 132Whole-Body Irradiation 116Mycophenolic Acid 115Busulfan 112Doxorubicin 109Tacrolimus 106Mercaptopurine 106Cyclosporine 95Radiotherapy 93Melphalan 93Rituximab 90pegaspargase 88Prednisone 85Asparaginase 84Daunorubicin 82Granulocyte Colony-Stimulating Factor 74blinatumomab 72Antilymphocyte Serum 71Calcium Dobesilate 69Clofarabine 58Thiotepa 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Calcifediol × Clear all
NCT05340985 2022-04-22

Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis

Tehran University of Medical Sciences

Phase 4 Unknown
54 enrolled
LymphoidOther hematologic neoplasm

Multiple Sclerosis, Relapsing-Remitting, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡